Estimated magnitude of diversion and abuse of opioids relative to benzodiazepines in France.

[1]  M. Lapeyre-Mestre,et al.  Monitoring of benzodiazepine diversion using a multi-indicator approach , 2011, International clinical psychopharmacology.

[2]  J. Micallef,et al.  Evolution of opioids reimbursement since 2004 from the National Database of the General Health Insurance System. , 2011, Therapie.

[3]  Matt Schiller,et al.  Societal costs of prescription opioid abuse, dependence, and misuse in the United States. , 2011, Pain medicine.

[4]  J. Micallef,et al.  Which indicators can public health authorities use to monitor prescription drug abuse and evaluate the impact of regulatory measures? Controlling High Dosage Buprenorphine abuse. , 2011, Drug and alcohol dependence.

[5]  L. Manchikanti,et al.  Therapeutic use, abuse, and nonmedical use of opioids: a ten-year perspective. , 2010, Pain physician.

[6]  L. Nelson,et al.  Prescription Drug Abuse: Insight Into the Epidemic , 2010, Clinical pharmacology and therapeutics.

[7]  M. Lapeyre-Mestre,et al.  Assessment of abuse potential of benzodiazepines from a prescription database using ‘doctor shopping’ as an indicator , 2010, CNS drugs.

[8]  N. Dasgupta,et al.  OPIOIDS, SUBSTANCE ABUSE & ADDICTIONS SECTION Original Research Article Post-marketing Surveillance of Methadone and Buprenorphine in the United States , 2010 .

[9]  B. Bégaud,et al.  Pharmacoepidemiological research using French reimbursement databases: yes we can! , 2010, Pharmacoepidemiology and drug safety.

[10]  H. Breivik,et al.  Increasing use of opioids from 2004 to 2007 – Pharmacoepidemiological data from a complete national prescription database in Norway , 2010, European journal of pain.

[11]  L. Radbruch,et al.  Formulary availability and regulatory barriers to accessibility of opioids for cancer pain in Europe: a report from the ESMO/EAPC Opioid Policy Initiative. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  M. Singleton,et al.  Surveillance of methadone‐related poisonings in Kentucky using multiple data sources , 2010, Pharmacoepidemiology and Drug Safety.

[13]  R. Dart.  Monitoring risk: post marketing surveillance and signal detection. , 2009, Drug and alcohol dependence.

[14]  J. Micallef,et al.  Estimation of clonazepam abuse liability: a new method using a reimbursed drug database , 2009, International clinical psychopharmacology.

[15]  M. Lapeyre-Mestre,et al.  Second Meeting of the French CEIP (Centres d'Évaluation et d'Information sur la Pharmacodépendance). Part I: How to Evaluate and Prevent the Abuse and Dependence on Hypnotic/Anxiolytic Drugs? , 2009, Therapie.

[16]  A. Muñoz,et al.  Integrating nine prescription opioid analgesics and/or four signal detection systems to summarize statewide prescription drug abuse in the United States in 2007 , 2009, Pharmacoepidemiology and drug safety.

[17]  J. Mounteney,et al.  Earlier warning: a multi-indicator approach to monitoring trends in the illicit use of medicines. , 2009, The International journal on drug policy.

[18]  O. Blin,et al.  Impact of a prescription monitoring program on doctor‐shopping for high dosage buprenorphine , 2009, Pharmacoepidemiology and drug safety.

[19]  M. Auriacombe,et al.  Benzodiazepine use among opiate-dependent subjects in buprenorphine maintenance treatment: correlates of use, abuse and dependence. , 2009, Drug and alcohol dependence.

[20]  J. Benneyan,et al.  National addictions vigilance intervention and prevention program (NAVIPPRO™): a real‐time, product‐specific, public health surveillance system for monitoring prescription drug abuse , 2008, Pharmacoepidemiology and drug safety.

[21]  P. Jolliet,et al.  [Not Available]. , 2008, Therapie.

[22]  M. Mallaret,et al.  Abus et dépendances aux produits psychoactifs : étude de consommations à travers l'enquête OPPIDUM 2004 du réseau des CEIP , 2007 .

[23]  Richard C Dart,et al.  The development of a comprehensive risk-management program for prescription opioid analgesics: researched abuse, diversion and addiction-related surveillance (RADARS). , 2007, Pain medicine.

[24]  M. Lapeyre-Mestre,et al.  Survey of Forged Prescriptions to Investigate Risk of Psychoactive Medications Abuse in France , 2007, Drug safety.

[25]  C. Brunelli,et al.  Opioid purchases and expenditure in nine western European countries: ‘Are we killing off morphine?’ , 2005, Palliative medicine.

[26]  H. Wechsler,et al.  Non-medical use of prescription stimulants among US college students: prevalence and correlates from a national survey. , 2005, Addiction.

[27]  Nicholas Moore,et al.  Patterns and correlates of benzodiazepine use in the French general population , 2004, European Journal of Clinical Pharmacology.

[28]  J. Micallef,et al.  Assessment of doctor‐shopping for high dosage buprenorphine maintenance treatment in a French region: development of a new method for prescription database , 2004, Pharmacoepidemiology and drug safety.

[29]  P. Giudice.  Cutaneous complications of intravenous drug abuse. , 2004 .

[30]  K. Foley,et al.  College on Problems of Drug Dependence taskforce on prescription opioid non-medical use and abuse: position statement. , 2003, Drug and alcohol dependence.

[31]  J. Micallef,et al.  Buprenorphine prescription by general practitioners in a French region. , 2002, Drug and alcohol dependence.

[32]  M. Lapeyre-Mestre,et al.  Forged medical prescriptions in a community pharmacy network in Midi-Pyrénées area: assessment of a falsification ratio , 2002, European Journal of Clinical Pharmacology.

[33]  J. Micallef,et al.  Comparison of methadone and high dosage buprenorphine users in French care centres. , 2001, Addiction.

[34]  L. Letenneur,et al.  Benzodiazepine use in an elderly community-dwelling population , 2001, European Journal of Clinical Pharmacology.

[35]  J. Micallef,et al.  Observation of Psychoactive Substance Consumption: Methods and Results of the French OPPIDUM Programme , 2001, European Addiction Research.

[36]  Patrick M. O'Malley,et al.  Monitoring the Future National Results on Adolescent Drug Use: Overview of Key Findings, 2004. , 2003 .

[37]  D A Zarin,et al.  Prescribing trends in psychotropic medications: primary care, psychiatry, and other medical specialties. , 1998, JAMA.

[38]  T. Davies,et al.  ABC of mental health , 1998 .

[39]  R. Griffiths,et al.  Benzodiazepine self-administration in humans and laboratory animals – implications for problems of long-term use and abuse , 1997, Psychopharmacology.

[40]  M. Ashworth,et al.  ABC of mental health: Addiction and dependence—II: Alcohol , 1997, BMJ.

[41]  M. Ashworth,et al.  ABC of mental health: Addiction and dependence—I: Illicit drugs , 1997, BMJ.

[42]  S W Hinkley,et al.  Drug abuse warning network. , 1981, Archives of general psychiatry.

[43]  M. Fonton.  Provence-Alpes-Côte-d'Azur , 1976 .